Literature DB >> 24571199

Long-term inhibition of ethanol intake by the administration of an aldehyde dehydrogenase-2 (ALDH2)-coding lentiviral vector into the ventral tegmental area of rats.

Eduardo Karahanian1, Mario Rivera-Meza, Lutske Tampier, María Elena Quintanilla, Mario Herrera-Marschitz, Yedy Israel.   

Abstract

Previous studies suggest that acetaldehyde generated from ethanol in the brain is reinforcing. The present studies tested the feasibility of achieving a long-term reduction of chronic and post-deprivation binge ethanol drinking by a single administration into the brain ventral tegmental area (VTA) of a lentiviral vector that codes for aldehyde dehydrogenase-2 (ALDH2), which degrades acetaldehyde. The ALDH2 gene coding vector or a control lentiviral vector were microinjected into the VTA of rats bred for their alcohol preference. In the chronic alcohol administration model, naïve animals administered the control vector and subsequently offered 10% ethanol and water ingested 8-9 g ethanol/kg body weight/day. The single administration of the ALDH2-coding vector prior to allowing ethanol availability reduced ethanol drinking by 85-90% (P < 0.001) for the 45 days tested. In the post-deprivation binge-drinking model, animals that had previously consumed ethanol chronically for 81 days were administered the lentiviral vector and were thereafter deprived of ethanol for three 7-day periods, each interrupted by a single 60-minute ethanol re-access after the last day of each deprivation period. Upon ethanol re-access, control vector-treated animals consumed intoxicating 'binge' amounts of ethanol, reaching intakes of 2.7 g ethanol/kg body weight in 60 minutes. The administration of the ALDH2-coding vector reduced re-access binge drinking by 75-80% (P < 0.001). This study shows that endowing the ventral tegmental with an increased ability to degrade acetaldehyde greatly reduces chronic alcohol consumption and post-deprivation binge drinking for prolonged periods and supports the hypothesis that brain-generated acetaldehyde promotes alcohol drinking.
© 2014 Society for the Study of Addiction.

Entities:  

Keywords:  ADE; Acetaldehyde; VTA.; chronic ethanol intake; lentiviral vector

Mesh:

Substances:

Year:  2014        PMID: 24571199     DOI: 10.1111/adb.12130

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  12 in total

1.  Role of ethanol-derived acetaldehyde in operant oral self-administration of ethanol in rats.

Authors:  Alessandra T Peana; Valeria Porcheddu; Federico Bennardini; Antonio Carta; Michela Rosas; Elio Acquas
Journal:  Psychopharmacology (Berl)       Date:  2015-08-22       Impact factor: 4.530

2.  Systemic Adeno-Associated Virus-Mediated Gene Therapy Prevents the Multiorgan Disorders Associated with Aldehyde Dehydrogenase 2 Deficiency and Chronic Ethanol Ingestion.

Authors:  Yuki Matsumura; Na Li; Hanan Alwaseem; Odelya E Pagovich; Ronald G Crystal; Matthew B Greenblatt; Katie M Stiles
Journal:  Hum Gene Ther       Date:  2020-01-28       Impact factor: 5.695

Review 3.  Gene and cell therapy on the acquisition and relapse-like binge drinking in a model of alcoholism: translational options.

Authors:  María Elena Quintanilla; Fernando Ezquer; Paola Morales; Mario Rivera-Meza; Eduardo Karahanian; Marcelo Ezquer; Mario Herrera-Marschitz
Journal:  Gene Ther       Date:  2019-02-28       Impact factor: 5.250

Review 4.  Alcohol-induced alterations in dopamine modulation of prefrontal activity.

Authors:  Heather Trantham-Davidson; L Judson Chandler
Journal:  Alcohol       Date:  2015-10-23       Impact factor: 2.405

5.  Primum Non Nocere: Should Gene Therapy Be Used to Prevent Potentially Fatal Disease but Enable Potentially Destructive Behavior?

Authors:  Inmaculada de Melo-Martin; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2021-04-26       Impact factor: 4.793

Review 6.  Can gene therapy be used to prevent cancer? Gene therapy for aldehyde dehydrogenase 2 deficiency.

Authors:  Rachel A Montel; Carlos Munoz-Zuluaga; Katie M Stiles; Ronald G Crystal
Journal:  Cancer Gene Ther       Date:  2021-11-19       Impact factor: 5.854

7.  Involvement of dopamine D2 receptors in addictive-like behaviour for acetaldehyde.

Authors:  Anna Brancato; Fulvio Plescia; Rosa Anna Maria Marino; Giuseppe Maniaci; Michele Navarra; Carla Cannizzaro
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

Review 8.  From Ethanol to Salsolinol: Role of Ethanol Metabolites in the Effects of Ethanol.

Authors:  Alessandra T Peana; Michela Rosas; Simona Porru; Elio Acquas
Journal:  J Exp Neurosci       Date:  2016-11-20

9.  Racemic Salsolinol and its Enantiomers Act as Agonists of the μ-Opioid Receptor by Activating the Gi Protein-Adenylate Cyclase Pathway.

Authors:  Pablo Berríos-Cárcamo; María E Quintanilla; Mario Herrera-Marschitz; Vasilis Vasiliou; Gerald Zapata-Torres; Mario Rivera-Meza
Journal:  Front Behav Neurosci       Date:  2017-01-23       Impact factor: 3.558

Review 10.  Mystic Acetaldehyde: The Never-Ending Story on Alcoholism.

Authors:  Alessandra T Peana; María J Sánchez-Catalán; Lucia Hipólito; Michela Rosas; Simona Porru; Federico Bennardini; Patrizia Romualdi; Francesca F Caputi; Sanzio Candeletti; Ana Polache; Luis Granero; Elio Acquas
Journal:  Front Behav Neurosci       Date:  2017-05-11       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.